Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation

Journal of Controlled Release

Volumn 229, Issue , 2016, Pages 10-22

  Ravar, Fatemeh ^a   Saadat, Ebrahim ^a   Gholami, Mehdi ^b   Dehghankelishadi, Pouya ^a,e   Mahdavi, Mehdi ^c   Azami, Samira ^d   Dorkoosh, Farid A ^a,e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Hyaluronic acid; Liposome; Paclitaxel; Targeted drug delivery

Indexed keywords

CELLS; CHEMOTHERAPY; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG PRODUCTS; ENCAPSULATION; LIPOSOMES; ORGANIC ACIDS; PARTICLE SIZE; TUMORS;

BREAST CANCER; CELLULAR INTERNALIZATION; CONFOCAL LASER SCANNING MICROSCOPY; ENCAPSULATION EFFICIENCY; FLOW CYTOMETRY ANALYSIS; NEGATIVE ZETA POTENTIALS; PACLITAXEL; TARGETED DRUG DELIVERY;

HYALURONIC ACID;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; COUMARIN; HERMES ANTIGEN; HYALURONIC ACID; NANOCOATING; PACLITAXEL; ANTINEOPLASTIC AGENT; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER LOCALIZATION; CANCER SIZE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CHEMICAL BINDING; CHEMICAL STRUCTURE; CIRCULATION TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG TOLERABILITY; ENDOCYTOSIS; EX VIVO STUDY; FREEZE DRYING; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDRODYNAMICS; HYDROPHILICITY; HYDROPHOBICITY; IC50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; M PHASE CELL CYCLE CHECKPOINT; MOLECULAR STABILITY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE STUDY; STATIC ELECTRICITY; SURFACE CHARGE; SURFACE PROPERTY; TREATMENT OUTCOME; TREATMENT RESPONSE; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; HYALURONIC ACID; LIPOSOMES; MICE, INBRED BALB C; PACLITAXEL; TUMOR BURDEN;

EID: 84961588780     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.03.012     Document Type: Article

References (70)

1. S. Murray, E. Briasoulis, H. Linardou, D. Bafaloukos, and C. Papadimitriou Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies Cancer Treat. Rev. 38 2012 890 903
2. S.S. Chakravarthi, and D.H. Robinson Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles Int. J. Pharm. 409 2011 111 120
3. K.H.R. Tkaczuk Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer Clin. Ther. 31 2009 2273 2289
4. A. Muñoz, F. Sojo, D.R.M. Arenas, V.V. Kouznetsov, and F. Arvelo Cytotoxic effects of new trans-2, 4-diaryl-r-3-methyl-1, 2, 3, 4-tetrahydroquinolines and their interaction with antitumoral drugs gemcitabine and paclitaxel on cellular lines of human breast cancer Chem. Biol. Interact. 189 2011 215 221
5. N.S. El Saghir, A. Tfayli, H.A. Hatoum, Z. Nachef, P. Dinh, and A. Awada Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives Crit. Rev. Oncol. Hematol. 80 2011 433 449
6. Z. Lin, W. Gao, H. Hu, K. Ma, B. He, W. Dai, X. Wang, J. Wang, X. Zhang, and Q. Zhang Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity J. Control. Release 174 2014 161 170
7. Z. Wang Taxane resistance in breast cancer Cancer Cell Microenviron. 1 2014 10.14800/ccm.14126
8. C. Wang, Y. Wang, Y. Wang, M. Fan, F. Luo, and Z. Qian Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel Int. J. Pharm. 414 2011 251 259
9. S.P. Akhlaghi, S. Saremi, S.N. Ostad, R. Dinarvand, and F. Atyabi Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines Nanomed. Nanotechnol. Biol. Med. 6 2010 689 697
10. T. Luo, J. Wang, Y. Yin, H. Hua, J. Jing, X. Sun, M. Li, Y. Zhang, and Y. Jiang (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma 2010
11. S.C. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, S.W. Kim, and M.H. Seo In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy J. Control. Release 72 2001 191 202
12. P. Ma, S.R. Benhabbour, L. Feng, and R.J. Mumper 2′-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer Cancer Lett. 334 2013 253 262
13. S.S. Chakravarthi, S. De, D.W. Miller, and D.H. Robinson Comparison of anti-tumor efficacy of paclitaxel delivered in nano-and microparticles Int. J. Pharm. 383 2010 37 44
14. T. Hamaguchi, Y. Matsumura, M. Suzuki, K. Shimizu, R. Goda, I. Nakamura, I. Nakatomi, M. Yokoyama, K. Kataoka, and T. Kakizoe NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Br. J. Cancer 92 2005 1240 1246
15. T. Yang, F.-D. Cui, M.-K. Choi, J.-W. Cho, S.-J. Chung, C.-K. Shim, and D.-D. Kim Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation Int. J. Pharm. 338 2007 317 326
16. J. Lu, Y. Huang, W. Zhao, R.T. Marquez, X. Meng, J. Li, X. Gao, R. Venkataramanan, Z. Wang, and S. Li PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers Biomaterials 34 2013 1591 1600
17. M. Shahin, S. Ahmed, K. Kaur, and A. Lavasanifar Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel Biomaterials 32 2011 5123 5133
18. V.P. Torchilin Multifunctional nanocarriers Adv. Drug Deliv. Rev. 64 2012 302 315
19. T. Tanaka, S. Shiramoto, M. Miyashita, Y. Fujishima, and Y. Kaneo Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME) Int. J. Pharm. 277 2004 39 61
20. S. Meng, B. Su, W. Li, Y. Ding, L. Tang, W. Zhou, Y. Song, and Z. Caicun Integrin-targeted paclitaxel nanoliposomes for tumor therapy Med. Oncol. 28 2011 1180 1187
21. T. Shigehiro, T. Kasai, M. Murakami, S.C. Sekhar, Y. Tominaga, M. Okada, T. Kudoh, A. Mizutani, H. Murakami, and D.S. Salomon Efficient drug delivery of paclitaxel glycoside: A novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation PLoS One 9 2014 e107976
22. P. Zhao, H. Wang, M. Yu, S. Cao, F. Zhang, J. Chang, and R. Niu Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: In vitro and in vivo evaluation Pharm. Res. 27 2010 1914 1926
23. K.Y. Choi, K.H. Min, H.Y. Yoon, K. Kim, J.H. Park, I.C. Kwon, K. Choi, and S.Y. Jeong PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo Biomaterials 32 2011 1880 1889
24. K.Y. Choi, H. Chung, K.H. Min, H.Y. Yoon, K. Kim, J.H. Park, I.C. Kwon, and S.Y. Jeong Self-assembled hyaluronic acid nanoparticles for active tumor targeting Biomaterials 31 2010 106 114
25. Y. Tiantian, Z. Wenji, S. Mingshuang, Y. Rui, S. Shuangshuang, M. Yuling, Y. Jianhua, Y. Xinggang, W. Shujun, and P. Weisan Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: Influence of formulation factors on the lymphatic targeting Int. J. Pharm. 471 2014 245 257
26. Y. Liu, J. Sun, W. Cao, J. Yang, H. Lian, X. Li, Y. Sun, Y. Wang, S. Wang, and Z. He Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery Int. J. Pharm. 421 2011 160 169
27. X.-y. Yang, Y.-x. Li, M. Li, L. Zhang, L.-x. Feng, and N. Zhang Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer Cancer Lett. 334 2013 338 345
28. R.E. Eliaz, and F.C. Szoka Liposome-encapsulated doxorubicin targeted to CD44 a strategy to kill CD44-overexpressing tumor cells Cancer Res. 61 2001 2592 2601
29. Y. Zhao, T. Zhang, S. Duan, N.M. Davies, and M.L. Forrest CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy Nanomed. Nanotechnol. Biol. Med. 10 2014 1221 1230
30. D. Peer, and R. Margalit Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models Neoplasia (New York, NY) 6 2004 343
31. A.D. Wojcicki, H. Hillaireau, T.L. Nascimento, S. Arpicco, M. Taverna, S. Ribes, M. Bourge, V. Nicolas, A. Bochot, and C. Vauthier Hyaluronic acid-bearing lipoplexes: Physico-chemical characterization and in vitro targeting of the CD44 receptor J. Control. Release 162 2012 545 552
32. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
33. A. Smirnov, M.D. Solga, J. Lannigan, and A.K. Criss An improved method for differentiating cell-bound from internalized particles by imaging flow cytometry J. Immunol. Methods 2015
34. J. Zhou, W.-Y. Zhao, X. Ma, R.-J. Ju, X.-Y. Li, N. Li, M.-G. Sun, J.-F. Shi, C.-X. Zhang, and W.-L. Lu The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer Biomaterials 34 2013 3626 3638
35. L.-M. Luo, Y. Huang, B.-X. Zhao, X. Zhao, Y. Duan, R. Du, K.-F. Yu, P. Song, Y. Zhao, and X. Zhang Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel Biomaterials 34 2013 1102 1114
36. Y. Yoshizawa, Y. Kono, K.-i. Ogawara, T. Kimura, and K. Higaki PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy Int. J. Pharm. 412 2011 132 141
37. H. Maeda SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy Adv. Drug Deliv. Rev. 46 2001 169 185
38. D.A. Ossipov Nanostructured hyaluronic acid-based materials for active delivery to cancer Expert Opin. Drug Deliv. 7 2010 681 703
39. T. Yang, M.-K. Choi, F.-D. Cui, J.S. Kim, S.-J. Chung, C.-K. Shim, and D.-D. Kim Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome J. Control. Release 120 2007 169 177
40. Y. Wang, X. Li, L. Wang, Y. Xu, X. Cheng, and P. Wei Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery Int. J. Nanomedicine 6 2011 1497
41. S. Lim, G.P. Martin, D. Berry, and M. Brown Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan J. Control. Release 66 2000 281 292
42. K. Rege, and I.L. Medintz Methods in Bioengineering: Nanoscale Bioengineering and Nanomedicine 2014 Artech House
43. R. Kunstfeld, G. Wickenhauser, U. Michaelis, M. Teifel, W. Umek, K. Naujoks, K. Wolff, and P. Petzelbauer Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model J. Investig. Dermatol. 120 2003 476 482
44. S. Arpicco, C. Lerda, E. Dalla Pozza, C. Costanzo, N. Tsapis, B. Stella, M. Donadelli, I. Dando, E. Fattal, and L. Cattel Hyaluronic acid-coated liposomes for active targeting of gemcitabine Eur. J. Pharm. Biopharm. 85 2013 373 380
45. E. Bajelan, A. Haeri, A.M. Vali, S.N. Ostad, and S. Dadashzadeh Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance J. Pharm. Pharm. Sci. 15 2012 568 582
46. E. Saadat, M. Amini, M.R. Khoshayand, R. Dinarvand, and F.A. Dorkoosh Synthesis and optimization of a novel polymeric micelle based on hyaluronic acid and phospholipids for delivery of paclitaxel, in vitro and in-vivo evaluation Int. J. Pharm. 475 2014 163 173
47. V.P. Torchilin Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate Adv. Drug Deliv. Rev. 57 2005 95 109
48. K. Cohen, R. Emmanuel, E. Kisin-Finfer, D. Shabat, and D. Peer Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters ACS Nano 8 2014 2183 2195
49. S.C. Ghosh, S. Neslihan Alpay, and J. Klostergaard CD44: A validated target for improved delivery of cancer therapeutics Expert Opin. Ther. Targets 16 2012 635 650
50. X. Yang, A. Singh, E. Choy, F.J. Hornicek, M.M. Amiji, and Z. Duan MDR1 siRNA Loaded Hyaluronic Acid-based CD44 Targeted Nanoparticle Systems Circumvent Paclitaxel Resistance in Ovarian Cancer, Scientific Reports, 5 2015
51. K.K. Vangara, J.L. Liu, and S. Palakurthi Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer Anticancer Res. 33 2013 2425 2434
52. E. Dalla Pozza, C. Lerda, C. Costanzo, M. Donadelli, I. Dando, E. Zoratti, M.T. Scupoli, S. Beghelli, A. Scarpa, and E. Fattal Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity Biochim. Biophys. Acta Biomembr. 1828 2013 1396 1404
53. X. Zhang, S. Guo, R. Fan, M. Yu, F. Li, C. Zhu, and Y. Gan Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells Biomaterials 33 2012 7103 7114
54. X. Han, Z. Li, J. Sun, C. Luo, L. Li, Y. Liu, Y. Du, S. Qiu, X. Ai, and C. Wu Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: Probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation J. Control. Release 197 2015 29 40
55. C. Riccardi, and I. Nicoletti Analysis of apoptosis by propidium iodide staining and flow cytometry Nat. Protoc. 1 2006 1458 1461
56. E. Harper, W. Dang, R.G. Lapidus, and R.I. Garver Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice Clin. Cancer Res. 5 1999 4242 4248
57. M. Markman, and T.M. Mekhail Paclitaxel in cancer therapy Expert. Opin. Pharmacother. 3 2002 755 766
58. W. Fan Possible mechanisms of paclitaxel-induced apoptosis Biochem. Pharmacol. 57 1999 1215 1221
59. F. Yan, L. Li, Z. Deng, Q. Jin, J. Chen, W. Yang, C.-K. Yeh, J. Wu, R. Shandas, and X. Liu Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers J. Control. Release 166 2013 246 255
60. I. Texier, M. Goutayer, A. Da Silva, L. Guyon, N. Djaker, V. Josserand, E. Neumann, J. Bibette, and F. Vinet Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence imaging J. Biomed. Opt. 14 2009 (054005-054005-054011)
61. L.-m. Han, J. Guo, L.-j. Zhang, Q.-s. Wang, and X.-l. Fang Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123 Acta Pharmacol. Sin. 27 2006 747 753
62. K. Xiao, J. Luo, W.L. Fowler, Y. Li, J.S. Lee, L. Xing, R.H. Cheng, L. Wang, and K.S. Lam A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer Biomaterials 30 2009 6006 6016
63. L. Chen, X. Sha, X. Jiang, Y. Chen, Q. Ren, and X. Fang Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: Optimization and in vitro, in vivo evaluation Int. J. Nanomedicine 8 2013 73
64. M.E. Davis, and D.M. Shin Nanoparticle therapeutics: An emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
65. S. Ganesh, A.K. Iyer, F. Gattacceca, D.V. Morrissey, and M.M. Amiji In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles J. Control. Release 172 2013 699 706
66. G. Saravanakumar, K.H. Min, D.S. Min, A.Y. Kim, C.-M. Lee, Y.W. Cho, S.C. Lee, K. Kim, S.Y. Jeong, and K. Park Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: Synthesis, characterization, and in vivo biodistribution J. Control. Release 140 2009 210 217
67. M.-Y. Yang, C.-J. Wang, N.-F. Chen, W.-H. Ho, F.-J. Lu, and T.-H. Tseng Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3 Chem. Biol. Interact. 213 2014 60 68
68. J. Wu, Q. Liu, and R.J. Lee A folate receptor-targeted liposomal formulation for paclitaxel Int. J. Pharm. 316 2006 148 153
69. W. Zhang, Y. Shi, Y. Chen, S. Yu, J. Hao, J. Luo, X. Sha, and X. Fang Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance Eur. J. Pharm. Biopharm. 75 2010 341 353
70. D. Peer, and R. Margalit Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models Int. J. Cancer 108 2004 780 789